Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS

MLA

Philippe Jacqmin, et al. “Evidence of NI-0101 Pharmacological Activity, an Anti-TLR4 Antibody, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Receiving LPS.” Clinical Pharmacology and Therapeutics, vol. 101, no. 2, June 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d2256c02a834b2597b28b6124036108e&authtype=sso&custid=ns315887.

APA

Philippe Jacqmin, C de Min, Emmanuel Monnet, Joannes A. A. Reijers, Matthijs Moerland, Geneviève Lapeyre, J. Burggraaf, K de Graaf, & E van Poelgeest. (2016). Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS. Clinical Pharmacology and Therapeutics, 101(2).

Chicago

Philippe Jacqmin, C de Min, Emmanuel Monnet, Joannes A. A. Reijers, Matthijs Moerland, Geneviève Lapeyre, J. Burggraaf, K de Graaf, and E van Poelgeest. 2016. “Evidence of NI-0101 Pharmacological Activity, an Anti-TLR4 Antibody, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Receiving LPS.” Clinical Pharmacology and Therapeutics 101 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d2256c02a834b2597b28b6124036108e&authtype=sso&custid=ns315887.